Cookies on this website
We use cookies to ensure that we give you the best experience on our website. If you click 'Continue' we'll assume that you are happy to receive all cookies and you won't see this message again. Click 'Find out more' for information on how to change your cookie settings.
Image of Alchemab's senior scientist, Jorge Dias with Alchemab logo

Alchemab Therapeutics, a resident company at Oxford's BioEscalator, has been shortlisted as a finalist in the Best Biotech Start-up category for the OBN Awards 2020.

Alchemab joined the BioEscalator community in December 2019, is focused on discovering and developing novel therapeutics for patients with a range of hard-to-treat diseases. Their innovative approach involves investigating healthy individuals to discover naturally protective antibodies. 

Senior Scientist at Alchemab, Jorge Dias commented, 'We feel honoured to be shortlisted by OBN, especially as there are so many great start-ups out there right now.’

Alchemab has recently used their technology to identify potential therapeutic targets in the fight against Covid.  For information on Alchemab's Covid work, click here.

BioEscalator alumnus company OMass Therapeutics, who use mass spectrometry technology to drive drug discovery in the fields of immunology and rare diseases, has also been shortlisted for an award in the Best Emerging Biotech category.

The official judging panel will now assess the final entries, the winner in each category will be announced in February 2021. The in-person event planned for 26th November at the Royal Lancaster Hotel, London has been postponed due to the latest Covid-19 restrictions. 

The BioEscalator wishes them both the very best of luck.

 

For more information on Alchemab and OMass, please visit our Companies page.